Posted by Michael Wonder on 29 Sep 2023
Fabre-Kramer Pharmaceuticals announces FDA approval of Exxua, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults
28 September 2023 - Exxua is the first new chemical entity utilising this single mechanism approved for the treatment of major depressive disorder.
Fabre-Kramer Pharmaceuticals is pleased to announce that the US FDA has approved Exxua (gepirone hydrochloride extended-release tablets) for the treatment of major depressive disorder in adults.
